Risk Minimisation Material: Patient booklet for the use of Lucentis (ranibizumab) for proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO)

This document helps patients understand the product, the condition, and the potential adverse effects from treatment. Patients should contact their doctor as soon as possible should eye pain, light sensitivity, ocular surface drying or increasing redness occur.

SPS commentary:

Separate patient booklets for use in choroidal neovascularisation (CNV) and retinal vein occlusion (RVO) have been produced



Resource links:

Patient information booklet for Lucentis for CNV

Patient information booklet for Lucentis for RVO